• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    3/12/24 9:05:56 AM ET
    $ACAD
    $BVS
    $CTMX
    $FNCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ACAD alert in real time by email

    Gainers

    • Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. The company's market cap stands at $51.5 million.
    • Assure Hldgs (NASDAQ:IONM) stock increased by 73.02% to $0.59. The market value of their outstanding shares is at $3.9 million.
    • Telomir Pharmaceuticals (NASDAQ:TELO) shares increased by 24.89% to $8.58. The market value of their outstanding shares is at $262.6 million.
    • Bioventus (NASDAQ:BVS) shares increased by 16.0% to $6.16. The market value of their outstanding shares is at $387.8 million. The company's, Q4 earnings came out today.
    • Genelux (NASDAQ:GNLX) stock increased by 14.79% to $7.45. The company's market cap stands at $199.0 million.
    • Kineta (NASDAQ:KA) stock moved upwards by 14.37% to $0.79. The company's market cap stands at $8.2 million.

    Losers

    • Renalytix (NASDAQ:RNLX) shares fell 27.2% to $0.83 during Tuesday's pre-market session. The market value of their outstanding shares is at $41.4 million.
    • CytomX Therapeutics (NASDAQ:CTMX) stock declined by 17.63% to $2.07. The company's market cap stands at $138.5 million. As per the press release, Q4 earnings came out yesterday.
    • Psyence Biomedical (NASDAQ:PBM) shares fell 17.52% to $1.46. The market value of their outstanding shares is at $19.5 million.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) stock fell 16.46% to $20.16. The market value of their outstanding shares is at $3.3 billion.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 16.3% to $0.56. The market value of their outstanding shares is at $51.3 million.
    • Finch Therapeutics Gr (NASDAQ:FNCH) shares fell 13.7% to $2.95. The company's market cap stands at $4.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $BVS
    $CTMX
    $FNCH

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Genelux Corporation
    $GNLX
    10/21/2025$16.00Buy
    Lake Street
    ACADIA Pharmaceuticals Inc.
    $ACAD
    10/21/2025$33.00Buy
    Citigroup
    CytomX Therapeutics Inc.
    $CTMX
    9/22/2025$6.00Overweight
    Cantor Fitzgerald
    CytomX Therapeutics Inc.
    $CTMX
    9/17/2025$3.50Overweight
    Barclays
    More analyst ratings

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by ACADIA Pharmaceuticals Inc.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/10/26 6:00:08 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by ACADIA Pharmaceuticals Inc.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/10/26 6:00:10 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, CHIEF LEGAL OFFICER, SEC Rhodes Jennifer J

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/10/26 6:00:16 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

    2/24/26 7:44:56 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    SEC Filings

    View All

    SEC Form S-8 filed by Bioventus Inc.

    S-8 - Bioventus Inc. (0001665988) (Filer)

    3/5/26 7:40:28 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Bioventus Inc.

    10-K - Bioventus Inc. (0001665988) (Filer)

    3/5/26 7:37:04 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bioventus Inc. (0001665988) (Filer)

    3/5/26 7:34:24 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & Head of R & D Klassen Preston bought $95,852 worth of shares (12,000 units at $7.99), increasing direct ownership by 33% to 48,055 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    6/4/25 5:00:15 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hagan Joseph P bought $54,260 worth of shares (50,000 units at $1.09), increasing direct ownership by 24% to 260,808 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    1/31/25 5:00:10 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baltimore David bought $20,787 worth of shares (19,610 units at $1.06), increasing direct ownership by 766% to 22,169 units (SEC Form 4)

    4 - Regulus Therapeutics Inc. (0001505512) (Issuer)

    1/31/25 5:00:06 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

    Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now accepting patients, call 1-833-4HOPETMS WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen,

    3/9/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to

    3/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Leadership Updates

    Live Leadership Updates

    View All

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Financials

    Live finance-specific insights

    View All

    CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to

    3/4/26 8:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

    DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/24/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive

    2/4/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BVS
    $CTMX
    $FNCH
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care